


AUTHOR QUERY FORM

	<p>Journal: BMCL</p> <p>Article Number: 23504</p>	<p>Please e-mail your responses and any corrections to:</p> <p>E-mail: corrections.eseo@elsevier.sps.co.in</p>
---	---	---

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

Location in article	Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof
<u>Q1</u>	Your article is registered as a regular item and is being processed for inclusion in a regular issue of the journal. If this is NOT correct and your article belongs to a Special Issue/Collection please contact d.barrett@elsevier.com immediately prior to returning your corrections.
<u>Q2</u>	The author names have been tagged as given names and surnames (surnames are highlighted in teal color). Please confirm if they have been identified correctly.
<u>Q3</u>	Please check the abstract and keywords that the copyeditor has assigned, and correct if necessary.
<u>Q4</u>	One or more sponsor names may have been edited to a standard format that enables better searching and identification of your article. Please check and correct if necessary.
<u>Q5</u>	The country names of the Grant Sponsors are provided below. Please check and correct if necessary. 'FAPESP' - 'Brazil'.
<u>Q6</u>	Please note that 'Materials and methods' section is cited in Table 2 legend but not provided in the text. Kindly check and correct if necessary.

Please check this box if you have no corrections to make to the PDF file


Thank you for your assistance.

Graphical abstract

The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins

pp xxx-xxx

Jorge A.N. Santos, Márcia Y. Kondo, Renato F. Freitas, Marcelo H. dos Santos,
Teodorico C. Ramalho, Diego M. Assis, Luiz Juliano, Maria A. Juliano, Luciano Puzer*





Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins

Jorge A. N. Santos^{a,†}, Márcia Y. Kondo^{b,†}, Renato F. Freitas^c, Marcelo H. dos Santos^d, Teodorico C. Ramalho^e, Diego M. Assis^b, Luiz Juliano^b, Maria A. Juliano^b, Luciano Puzer^{f,*}

^a Instituto Federal de Ciência, Tecnologia e Educação do Sul de Minas Gerais, Campus Inconfidentes, MG, Brazil

^b Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, SP, Brazil

^c Department of Biology, The Johns Hopkins University, Baltimore, MD, USA

^d Departamento de química, Universidade Federal de Viçosa, Viçosa, MG, Brazil

^e Departamento de química, Universidade Federal de Lavras, Lavras, MG, Brazil

^f Centro de Ciências Naturais e Humanas, Bloco Delta, Sala 210, Universidade Federal do ABC, Rua Arcturus 3, São Bernardo do Campo, SP 09606-070, Brazil

ARTICLE INFO

Article history:

Received 13 July 2015

Revised 12 January 2016

Accepted 14 January 2016

Available online xxx

Keywords:

Enzyme

Serine protease

Kallikrein

Inhibitor

Flavone

Molecular docking

Molecular dynamic simulation

ABSTRACT

The human tissue kallikreins (KLK1–KLK15) comprise a family of 15 serine peptidases detected in almost every tissue of the human body and that actively participate in many physiological and pathological events. Some kallikreins are involved in diseases for which no effective therapy is available, as for example, epithelial disorders, bacterial infections and in certain cancers metastatic processes. In recent years our group have made efforts to find inhibitors for all kallikreins, based on natural products and synthetic molecules, and all the inhibitors developed by our group presented a competitive mechanism of inhibition. Here we describe fukugetin, a natural product that presents a mixed-type mechanism of inhibition against KLK1 and KLK2. This type of inhibitor is gaining importance today, especially for the development of exosite-type inhibitors, which present potential to selectively inhibit the enzyme activity only against specific substrate.

© 2016 Published by Elsevier Ltd.

The family of the tissue kallikrein and kallikrein-related peptidases (KLKs), encoded by the largest contiguous cluster of protease genes in the human genome, consists of 15 homologous, single-chain, secreted serine proteases. They possess at least 30% sequence identity and the mature proteins are approximately of ~25–30 kDa, with similar structural characteristics and trypsin- or chymotrypsin-like specificities.^{1,2} KLKs are synthesized as zymogens, secreted and then proteolytically processed to generate the active form. Proteolytic activity of KLKs is also regulated by complex formation with endogenous plasma and tissue inhibitors such as α 2-macroglobulin and serpins, and/or inactivation through self-fragmentation.³ All KLKs have different expression patterns and physiological roles in different tissues with diverse functions and substrates. Based on KLK1–kininogen interaction, the crystal structures of KLKs complexes and the functional data define three distinct regions in the protease domain as important to recognition

of substrate and inhibitors; (i) the S1 pocket; (ii) kallikrein loop and S2–S4 pockets; (iii) S1'–2' pockets.⁴

The expression of KLKs occurs in many organs including skin, pancreas, colon, brain, breast and prostate, where epithelial cells mainly secrete them. Once secreted, KLKs remain in the pericellular space or enter body fluids such as saliva, sweat, milk, seminal plasma and cerebrospinal fluid.⁵ The physiological processes in which KLKs are involved include regulation of blood pressure (KLK1-mediated cleavage of kininogenase), extracellular-matrix remodeling (KLK3, 5, 6, 13 and 14) skin desquamation (KLK5, KLK7, and KLK14), neural plasticity (KLK6–8), semen liquefaction (PSA/KLK3- and KLK2-mediated cleavage of semenogelins) among others. KLKs are able to cleave and, consequently, to activate cell surface receptors and other proteases, being part of proteolytic cascades and signal transduction pathways and networks.^{6–11}

In addition to the so far described physiological roles of KLKs, their unusual expression and activity have been reported in various pathological conditions such as Alzheimer's disease and in many cancer-related processes, such as cell growth regulation, angiogenesis, invasion, and metastasis, being KLK3/PSA one of the most important biomarkers for prostate cancer.^{12–14} Thus,

* Corresponding author. Tel.: +55 11 2320 6238.

E-mail address: luciano.puzer@ufabc.edu.br (L. Puzer).

† Both authors contributed equally to this work.

the search for new KLKs inhibitors is necessary either to elucidate roles of KLKs in many physiological and pathological processes or to be used as potential therapy in many diseases.^{7,15} In recent years our group have described different competitive inhibitors for kallikreins, based on natural products and synthetic molecules.^{16–18}

Here we describe fukugetin, a natural product that presents a mixed-type mechanism of inhibition against KLK1 and KLK2. This type of inhibitor is gaining importance today, especially for the development of exosite-type inhibitors, which present potential to selectively inhibit the enzyme activity only against specific substrate. In this study, we report the inhibition of KLKs 1, 2, 3, 5, 6 and 7 activities by fukugetin (Table 1), compound isolated from *Garcinia brasiliensis*. Fukugetin is a plant flavonoids compound that consists of a naringenin covalently linked to a luteolin, that is a flavanone-(C-3 → C-8'')-flavone biflavonoid, like others biflavones, presents rigidity of benzopyranone moiety as well as flexibility between phenyl ring and benzopyranone and it was previously shown to be a potent inhibitor of cysteine proteases papain and cruzain with slow-binding and reversibility kinetics.¹⁹


Fukugetin was extracted and isolated from *G. brasiliensis* fruit as previously described.¹⁶ The fruits were collected at the herbarium of the University of Viçosa (latitude 20° 45' 14" south and longitude 42° 52' 55" west), Minas Gerais, Brazil. Mature kallikreins were expressed and purified from a baculovirus/insect cell line system as previously described.¹⁷ Enzymes concentrations were determined by the method of Bradford.²⁰ Purity and characterization of the enzymes were confirmed by SDS/PAGE, N-terminal sequencing, and mass spectrometry. Kallikrein proteolytic activity was monitored on the fluorescence resonance energy transfer (FRET) peptides, Abz-KLRSSQ-EDDnp (for KLK1, KLK2, KLK5 and KLK6) and Abz-KLYSSQ-EDDnp (for KLK3 and KLK7) as previously described.¹⁵ To measure the kinetic parameters, all kallikreins (final concentrations ~10 nM) were incubated with fukugetin in increasing concentrations (final concentrations were 1, 2, 6, 8 and 10 μM) in a final volume of 1 ml using as buffer 50 mM Tris, 1 mM EDTA, pH 7.5 at 37 °C. After 10 min of incubation, hydrolytic activity was assayed in a Hitachi F-2500 spectrofluorimeter by the addition of FRET peptides (in five different concentrations 0.25–10 μM). Fluorescence changes were monitored continuously at a λ_{ex} of 320 nm and λ_{em} of 420 nm. Furthermore, the IC₅₀ values were determined from plots of percent inhibition versus log inhibitor concentration and calculated by nonlinear regression using the KaleidaGraph program. This software was also used to calculate K_m and V_{max} values by nonlinear regression. Factors α, β and K_i for KLK1 and KLK2 inhibition were calculated using Eqs. 1 and 2, which describe a linear partial competitive inhibition [23], where K_S is the substrate dissociation constant:

$$\text{Slope} = \frac{K_s}{K_i V_{\max}} [I] + \frac{K_s}{V_{\max}} \quad (1)$$

$$\text{Intercept} = \frac{1}{\alpha K_i V_{\max}} [I] + \frac{1}{V_{\max}} \quad (2)$$

All experiments were performed in triplicate and the data are presented as mean ± standard error of mean. Summary of IC₅₀ values (Table 1) shows that all seven kallikreins tested were inhibited by fukugetin to a greater or lesser degree. KLK2 and KLK1 showed the lowest values of IC₅₀, 3.2 μM and 5.7 μM, respectively. To better understand the interaction between KLK1 and KLK2 with fukugetin, we performed a detailed kinetic study to determine the mechanism of inhibition. Lineweaver–Burk or double-reciprocal plots, 1/v versus 1/[I], for KLK1 and KLK2, are show in Figure 1. This type of plot is especially useful for distinguishing between competitive and noncompetitive inhibition and in the calculations of the kinetic parameters.²¹ The lines converge above the x axis to the same point in the second quadrant, for both enzymes, suggesting

Table 1
Inhibition of kallikreins by fukugetin



KLK	IC ₅₀ (μM)
KLK1	5.7 ± 0.2
KLK2	3.2 ± 0.1
KLK3	13 ± 0.8
KLK5	12.5 ± 1.1
KLK6	13.5 ± 0.3
KLK7	15 ± 0.5

IC₅₀ values were determined from plots of percent inhibition versus log inhibitor concentration, and calculated by nonlinear regression. Molecular structure of Fukugetin is indicated in red (Luteolin domain) and blue color (Naringenin domain).

that fukugetin acts as a mixed-type inhibitor for both enzymes, called linear partial competitive inhibition.²¹ In addition we also plotted the Eadie–Hofstee graph (Fig. S1) that confirmed the mixed-type inhibition.

This type of inhibition occurs when the inhibitor binds to both E and ES, but its affinity for these two forms of the enzyme are different (K_i ≠ αK_i) and ESI complex is nonproductive (Fig. 1c). K_m and V_{max} were determined at each fukugetin concentration, and the data are show in Table 2. Mixed-type inhibitor affects the parameters K_m (increase) and V_{max} (decrease), interfering with catalysis and substrate binding.²¹ To KLK1, K_m ranged between 0.65 ± 0.03 and 1.12 ± 0.1 μM; and V_{max} ranged between 450 ± 20 and 160 ± 12 μM·s⁻¹. In the case of KLK2, K_m ranged between 0.62 ± 0.02 and 1.20 ± 0.01 μM; and V_{max} ranged between 226 ± 10 and 79 ± 2 μM·s⁻¹. The factor α (Table 2), the parameter by which K_S changes when fukugetin interacts with the enzyme, was 1.6 ± 0.1 to KLK1 and 2.3 ± 0.2 to KLK2; and the factor β, the parameter by which k_{cat} is altered when the inhibitor interacts the enzyme, was equal to zero to both proteases. Since β is equal to zero, the secondary plots, 1/V_{max} and the K_m/V_{max} on the fukugetin concentration, for both kallikreins are linear (Supplementary material, Fig. S2), confirming linear partial competitive inhibition.²¹ The results of Table 2 also show that fukugetin binds KLK1 with a K_i of 3.6 μM ± 0.2 and binds KLK2 with 1.6 ± 0.1 μM.

In order to rationalize the observed mechanism of inhibition, we performed molecular docking combined with molecular dynamics simulations to identify the putative binding site of fukugetin bound to KLK1. Initially, AutoDock 4.2 was used to scan the entire protein surface (blind docking) to predict its binding mode. The resulting 300 conformations of the ligand were processed by the built-in clustering analysis, which showed that 79 of the docked conformations fall into three large clusters around the substrate pocket (Fig. 2a). The first pocket has 35 conformations coming from only one cluster (C1) while the second pocket contains 44 conformations and it is a combination of two clusters (C2 and C3), which differ only in the way the ligand binds. The mean binding energy for three clusters is -8.9 (C1), -8.5 (C2), and -6.5 kcal/mol (C3), respectively. Based on the calculated binding energy, it is possible to assume that the binding mode of fukugetin in C3 is less favorable. But, it is difficult to assess in which one of the other two cluster (C1 vs C2) the ligand has higher affinity, as both have




Figure 2. (a) Blind docking of fukugetin into the KLK1 identified two potential binding sites: Pose 1 (magenta) and pose 2 (cyan) are the lowest energy conformation from each of the two clusters. The surface of the enzyme is colored by atom type; (b) the MD-refined binding mode of pose 1; (c) the MD-refined binding mode of pose 2. Residues in the protein-binding pocket involved in specific interactions with fukugetin and hydrogen bonds (yellow dash line) are annotated.

Acknowledgement

We gratefully acknowledge financial support from FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo, Proc. 2013/10548-3).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2016.01.039>.

References and notes

1. Kontos, C. K.; Mavridis, K.; Talieri, M.; Scorilas, A. *Thromb. Haemost.* **2013**, *110*, 2013.
2. Li, H. X.; Hwang, B. Y.; Laxmikanthan, G.; Blaber, S. I.; Blaber, M.; Golubkov, P. A.; Ren, P.; Iverson, B. L.; Georgiou, G. *Protein Sci.* **2008**, *17*, 2008.
3. Clements, J. A.; Willemsen, N. M.; Myers, S. A.; Dong, Y. *Crit. Rev. Clin. Lab. Sci.* **2004**, *41*, 2004.
4. Pathak, M.; Wong, S. S.; Dreveny, I.; Emsley, J. *Thromb. Haemost.* **2013**, *110*, 2013.
5. Shaw, J. L.; Diamandis, E. P. *Clin. Chem.* **2007**, *53*, 2007.
6. Avgeris, M.; Mavridis, K.; Scorilas, A. *Biol. Chem.* **2012**, *393*, 2012.
7. Bhoola, K. D.; Figueroa, C. D.; Worthy, K. *Pharmacol. Rev.* **1992**, *44*, 1992.
8. Borgono, C. A.; Diamandis, E. P. *Cancer* **2004**, *4*, 2004.
9. Borgono, C. A.; Michael, I. P.; Shaw, J. L.; Luo, L. Y.; Ghosh, M. C.; Soosaipillai, A.; Grass, L.; Katsaros, D.; Diamandis, E. P. *J. Biol. Chem.* **2007**, *282*, 2007.
10. Pampalakis, G.; Scorilas, A.; Sotiropoulou, G. *Clin. Biochem.* **2008**, *41*, 2008.
11. Suzuki, J.; Yoshida, S.; Chen, Z. L.; Momota, Y.; Kato, K.; Hirata, A.; Shiosaka, S. *Neurosci. Res.* **1995**, *23*, 1995.
12. Gao, L.; Smith, R. S.; Chen, L. M.; Chai, K. X.; Chao, L.; Chao, J. *Biol. Chem.* **2010**, *391*, 2010.
13. Little, S. P.; Dixon, E. P.; Norris, F.; Buckley, W.; Becker, G. W.; Johnson, M.; Dobbins, J. R.; Wyrick, T.; Miller, J. R.; MacKellar, W.; Hepburn, D.; Corvalan, J.; McClure, D.; Liu, X.; Stephenson, D.; Clemens, J.; Johnstone, E. M. *J. Biol. Chem.* **1997**, *272*, 1997.
14. Stephan, C.; Jung, K.; Lein, M.; Diamandis, E. P. *Eur. J. Cancer* **2007**, *43*, 2007.
15. Angelo, P. F.; Lima, A. R.; Alves, F. M.; Blaber, S. I.; Scarisbrick, I. A.; Blaber, M.; Juliano, L.; Juliano, M. A. *J. Biol. Chem.* **2006**, *281*, 2006.
16. Freitas, R. F.; Teixeira, T. S.; Barros, T. G.; Santos, J. A.; Kondo, M. Y.; Juliano, M. A.; Juliano, L.; Blaber, M.; Antunes, O. A.; Abrahao, O., Jr.; Pinheiro, S.; Muri, E. M.; Puzer, L. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 2012.
17. Oliveira, J. P.; Freitas, R. F.; Melo, L. S.; Barros, T. G.; Santos, J. A.; Juliano, M. A.; Pinheiro, S.; Blaber, M.; Juliano, L.; Muri, E. M.; Puzer, L. *ACS Med. Chem. Lett.* **2014**, *5*, 2014.
18. Teixeira, T. S.; Freitas, R. F.; Abrahao, O., Jr.; Devienne, K. F.; de Souza, L. R.; Blaber, S. I.; Blaber, M.; Kondo, M. Y.; Juliano, M. A.; Juliano, L.; Puzer, L. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2011.
19. Assis, D. M.; Gontijo, V. S.; de Oliveira Pereira, I.; Santos, J. A.; Camps, I.; Nagem, T. J.; Ellena, J.; Izidoro, M. A.; dos Santos Tersariol, I. L.; de Barros, N. M.; Doriguetto, A. C.; dos Santos, M. H.; Juliano, M. A. *J. Enzyme Inhib. Med. Chem.* **2013**, *28*, 2013.
20. Bradford, M. M. *Anal. Biochem.* **1976**, *72*, 1976.
21. Segel, I. H. *Enzyme Kinetics Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems*; John Wiley & Sons: New York, 1993. pp 470–473.